Shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) have earned an average rating of “Buy” from the twelve ratings firms that are covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $39.20.

Several research firms have weighed in on DBVT. Stifel Nicolaus began coverage on DBV TECHNOLOGIE/S in a research note on Thursday. They issued a “buy” rating for the company. BidaskClub upgraded DBV TECHNOLOGIE/S from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 28th. ValuEngine upgraded DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a research note on Thursday, August 2nd. Morgan Stanley dropped their price target on DBV TECHNOLOGIE/S from $28.00 to $27.00 and set an “equal weight” rating for the company in a research note on Tuesday. Finally, Zacks Investment Research downgraded DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating in a research note on Friday, June 1st.

DBVT stock traded up $0.28 during midday trading on Friday, hitting $23.81. The company’s stock had a trading volume of 149,900 shares, compared to its average volume of 201,396. DBV TECHNOLOGIE/S has a 12 month low of $16.65 and a 12 month high of $50.57. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.37 and a quick ratio of 4.37. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -7.24 and a beta of 1.05.

Hedge funds have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd bought a new position in shares of DBV TECHNOLOGIE/S during the 2nd quarter valued at approximately $285,000. Exane Asset Management boosted its position in shares of DBV TECHNOLOGIE/S by 17.9% during the 2nd quarter. Exane Asset Management now owns 50,000 shares of the company’s stock valued at $964,000 after acquiring an additional 7,600 shares during the last quarter. Bailard Inc. bought a new position in shares of DBV TECHNOLOGIE/S during the 1st quarter valued at approximately $1,084,000. First Midwest Bank Trust Division boosted its position in shares of DBV TECHNOLOGIE/S by 36.7% during the 2nd quarter. First Midwest Bank Trust Division now owns 136,986 shares of the company’s stock valued at $2,642,000 after acquiring an additional 36,798 shares during the last quarter. Finally, Millennium Management LLC boosted its position in shares of DBV TECHNOLOGIE/S by 842.6% during the 1st quarter. Millennium Management LLC now owns 133,256 shares of the company’s stock valued at $3,074,000 after acquiring an additional 119,119 shares during the last quarter. Institutional investors and hedge funds own 44.67% of the company’s stock.

DBV TECHNOLOGIE/S Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Featured Article: Fundamental Analysis

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.